Orphenadrine citrate powder, also known as Orphenadrine ; Orfenadine citrate; N. N-dimethyl-2- [(2-methylphenyl) methoxy] ethylamine 2-hydroxy-1,2,3-tricarboxylate is a chemical substance that appears as a white or nearly white crystalline powder and is typically stored at 2-8 ° C. It is insoluble in water and slightly soluble in ethanol. As an orally effective non competitive NMDA receptor antagonist (which can penetrate the blood-brain barrier), Orfenadine citrate can relieve stiffness, pain, and discomfort caused by muscle strains, sprains, or other injuries, and is also used to alleviate tremors caused by Parkinson's disease. In addition, it also has good neuroprotective effects and can be used for research on neurodegenerative diseases. It also has certain antihistamine effects, as well as local anesthetic, antiemetic, and anticholinergic effects. However, compared to certain antihistamines, its antihistamine activity may be lower, while its anticholinergic effect is higher.
Orphenadrine Citrate Powder CAS 4682-36-4
Product Code: BM-2-5-076
English name: Orphenadrine Citrate
CAS number: 4682-36-4
Molecular formula: c24h31no8
Molecular weight: 461.5
EINECS Number: 225-137-5
Appearance: White or almost white crystalline powder
Enterprise standard: HPLC>99.5%, HNMR (please refer to COA or contact sales for details)
Product Code: 2922190900
Main markets: United States, Australia, Brazil, Japan, Germany, Indonesia, United Kingdom, New Zealand, Canada, etc.
Manufacturer: BLOOM TECH Yinchuan Factory
Technical Services: R&D Department-5
We provide Orphenadrine Citrate Powder CAS 4682-36-4 ,please refer to the following website for detailed specifications and product information.
What not to mix with orphenadrine citrate powder?
Orphenadrine citrate powder is an orally effective non competitive NMDA receptor antagonist that can alleviate stiffness, pain, and discomfort caused by muscle strains, sprains, or other injuries, and is also used to alleviate tremors caused by Parkinson's disease. However, it may interact with other drugs or substances when mixed, leading to reduced efficacy, increased side effects, or other adverse reactions. Here is an overview of some substances or drugs that cannot be mixed with Orfenadine citrate:
Orfenadine citrate has anticholinergic effects, so when used in combination with other anticholinergic drugs (such as atropine, scopolamine, etc.), it may enhance the anticholinergic effect, leading to worsening adverse reactions such as dry mouth, blurred vision, and difficulty urinating. Therefore, simultaneous use with these drugs should be avoided. Orfenadine citrate may have a sedative effect, and when used in combination with sedatives and sleeping pills (such as diazepam, clonazepam, etc.), it may enhance the sedative effect, leading to adverse reactions such as drowsiness, dizziness, and fatigue. Therefore, caution should be exercised when using these medications to avoid simultaneous use. Some antidepressants (such as tricyclic antidepressants) may have anticholinergic effects, and when used in combination with Orfenadine citrate, they may increase the risk of anticholinergic effects. In addition, antidepressants may also affect the metabolism and excretion of Orfenadine citrate, leading to increased drug concentrations and adverse reactions. Therefore, when using these medications, it is advisable to consult a doctor and adjust the dosage according to their advice or avoid simultaneous use.
Drug interactions
Orphenadrine citrate powder can be used to alleviate tremors caused by Parkinson's disease, but when used in combination with other anti Parkinson's drugs (such as levodopa, dopamine receptor agonists, etc.), it may interact with each other, affecting the efficacy or increasing adverse reactions. Therefore, when using these medications, it is advisable to consult a doctor and adjust the treatment plan according to their advice. Some antibiotics, such as aminoglycoside antibiotics, may interact with Orfenadine citrate, affecting the absorption, distribution, metabolism, and excretion of the drug. For example, aminoglycoside antibiotics may compete with Orfenadine citrate for tubular secretion, leading to increased drug concentrations and adverse reactions. Therefore, when using these medications, it is advisable to consult a doctor and adjust the dosage according to their advice or avoid simultaneous use. Diuretics (such as furosemide, hydrochlorothiazide, etc.) may increase renal excretion of Orfenadine citrate, leading to a decrease in drug concentration and weakened efficacy. Therefore, when using these medications, it is advisable to consult a doctor and adjust the dosage according to their advice or avoid simultaneous use.
Material interaction
Alcohol has a sedative effect, and when used in combination with Orfenadine citrate, it may enhance the sedative effect, leading to adverse reactions such as drowsiness, dizziness, and fatigue. In addition, alcohol may also affect the metabolism and excretion of Orfenadine citrate, leading to an increase in drug concentration and adverse reactions. Therefore, alcohol consumption should be avoided during the use of Orfenadine citrate. It has an excitatory effect, opposite to the sedative effect of Orfenadine citrate.
Material interaction
Therefore, caffeine may weaken the sedative effect of Orfenadine citrate and may lead to adverse reactions such as insomnia and anxiety. During the use of Orfenadine citrate, excessive intake of caffeine should be avoided. Nicotine and other components in tobacco may affect the metabolism and excretion of drugs, leading to an increase or decrease in drug concentration. In addition, smoking may exacerbate certain adverse reactions (such as dry mouth, blurred vision, etc.). Therefore, smoking should be avoided during the use of Orfenadine citrate.
Other precautions
The dosage of Orphenadrine citrate powder should be adjusted based on factors such as the patient's age, weight, condition, and liver and kidney function. When using, follow the doctor's advice and avoid increasing the dosage or prolonging the medication time on your own. Citrate Orfenadine may cause adverse reactions such as dry mouth, blurred vision, difficulty urinating, drowsiness, dizziness, and fatigue. During use, patients' symptoms should be closely monitored, and if serious adverse reactions occur, they should seek medical attention promptly. During the use of Orfenadine citrate, if other drugs or substances need to be used simultaneously, a doctor should be consulted and drug interaction monitoring should be conducted.
Other precautions
Doctors will develop appropriate treatment plans based on the patient's specific condition and the risk of drug interactions. For special populations such as pregnant women, breastfeeding women, children, and the elderly, caution should be exercised when using Orfenadine citrate. These populations may have high sensitivity to drugs and are prone to adverse reactions. Before use, consult a doctor and adjust the dosage or avoid use according to their advice. At the same time, it should be stored in a dry, cool, well ventilated place, away from direct sunlight and high temperatures. Before use, the packaging and expiration date of the medication should be checked to ensure its quality and safety.